In a medical landscape that’s full of precision drugs and detailed diagnoses, neurology is something of an outlier. Given how difficult it is to diagnose disorders of the nervous system, neurology has proven a particularly tricky branch of medicine. (Much of the public’s skepticism is understandable: Research suggests Parkinson’s, for example, has a 25% rate of misdiagnosis.)
A lack of objective tests and the highly subjective nature of available tools leads to imprecise and deferred diagnosis, resulting in late intervention, impaired patient care, and ineffective drug development.
Enter NeuraLight, a VC-backed startup that aims to digitize neurological evaluation and care. Cofounded by former Chorus.ai president Micha Breakstone, NeuraLight’s AI-driven platform integrates multiple digital markers to accelerate and improve drug development, monitoring, and precision care for patients with neurological disorders. The idea is that if you improve the diagnosis process, you can intervene earlier on, improving prognosis, and often, as in the case of relapsing-remitting MS, even changing the course of the disease.
To date, the company has raised over $30M from prominent VCs such as Koch Disruptive Technologies, Breyer Capital, Samsung Next, VSC, and Operator Partners, as well as angel investors including Instacart CEO Fidji Simo and and Lily Sarafan, cofounder of TheKey.
For Breakstone, the company’s mission isn’t just a business proposition; it’s personal. “After watching two of my grandparents battle with Alzheimer’s and Dementia, I began studying these diseases in depth, and it soon became clear to me that cures for these diseases are extremely hard to discover because they lack robust objective and sensitive measures,” he says. “That’s why we founded NeuraLight—to measure neurological disorders accurately and objectively, and bring precision medicine to neurology.”
Research spanning several decades and published in hundreds of peer-reviewed papers has established that oculometric markers—that is, biomarkers extracted from measuring micro-movements of the eye—can be used to diagnose and predict the progression of a wide range of neurological disorders. NeuraLight leverages proprietary Computer Vision and Deep Learning algorithms to simultaneously extract all relevant oculometric markers from facial videos captured with a standard webcam or smartphone.
These digital markers serve as a reliable proxy for currently used clinical endpoints, and will provide an accurate snapshot of a person’s neurological status, enabling pharmaceutical companies to introduce smart phenotyping, reduce misdiagnosis, and accurately and sensitively measure disease progression.
NeuraLight recently launched a trial in collaboration with publicly traded pharma company, NeuroSense. The goal of the trial is to establish whether NeuraLight can predict the progression of ALS using their platform. While official results have not yet been published, Breakstone says an initial analysis of NeuraLight’s measurements is extremely encouraging, and is in line with published literature.
“This will be a big step forward for us in establishing oculometrics as a sensitive and reliable biomarker for neurological disorders,” Breakstone says.
Login to add comment
Other posts in this group
When artificial intelligence first gained traction in the early 2010s,
You wake up in the morning and, first thing, you open your weather app. You close that pesky ad that opens first and check the forecast. You like your weather app, which shows hourly weather forec
How the Boomer wealth transfer could reshape global finance.
Born too late to ride the wave of postwar prosperity, but just early enough to watch the 2008 financial crisis decimate some
The Velvet Sundown is the most-talked-about band of the moment, but not for the reason you might expect.
The “indie rock band,” which has gained more than 634,000 Spotify lis
Sean “Diddy” Combs was convicted of prostitution-related offenses but acquitted of
A U.S. judge has ruled that China’s Huawei Technologies
Shares of U.K.’s Bytes Technology plunged over 27% on Wednesday after the IT firm said its operating profit for the first half of fiscal 2026 would be marginally lower due to delayed custome
